New trials, publications, preprints and grants on this target, month by month.
Publication
TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome.
4 Nov 2026· Expert review of anticancer therapy· PUBMED
Publication
Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer.
2 Nov 2026· Molecular pharmaceutics· PUBMED
Publication
High prevalence of TROP2 expression identifies EBV-positive gastric cancer as a candidate for TROP2-directed antibody-drug conjugates.
24 Oct 2026· Langenbeck's archives of surgery· PUBMED
Trial
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
16 Oct 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Nectin-4 and TROP-2 in bladder cancer: biomarkers for targeted therapy.
15 Oct 2026· Pathobiology : journal of immunopathology, molecular and cellular biology· PUBMED
Publication
Prognostic Significance of B7-H3, TROP2, and p16 Expression in Pleural Mesothelioma: Clinicopathological Correlations and Survival Outcomes.
15 Oct 2026· Journal of clinical medicine· PUBMED
Publication
Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
7 Oct 2026· Cancers· PUBMED
Publication
Expression of NECTIN-4 and TROP-2 in Resected Upper Tract Urothelial Carcinoma with and Without Preoperative Chemotherapy.
6 Oct 2026· European urology open science· PUBMED
Publication
Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies.
6 Oct 2026· Cureus· PUBMED
Trial
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
1 Oct 2026· PHASE2 · RECRUITING· CTGOV
Publication
Multi-parameter optimization of a novel anti-TROP2 MMAE antibody-drug-conjugate for solid tumor therapy.
30 Sept 2026· Frontiers in oncology· PUBMED
Preprint
Quantitative Systems Pharmacology Model for TROP-2 Targeted Antibody-Drug Conjugate in Triple-Negative Breast Cancer.
25 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018).
24 Sept 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
NECTIN4, TROP2 and PDL1 in Breast Cancer: Immunohistochemical Profiling and Clinical Associations.
22 Sept 2026· International journal of surgical pathology· PUBMED
Publication
TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes.
17 Sept 2026· ESMO gastrointestinal oncology· PUBMED
Publication
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.
13 Sept 2026· Clinical pharmacology and therapeutics· PUBMED
Publication
Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma.
7 Sept 2026· Diagnostics (Basel, Switzerland)· PUBMED
Trial
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
1 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Durable Intracranial Response to Sacituzumab Tirumotecan in HER2-Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report.
1 Sept 2026· Cancer reports (Hoboken, N.J.)· PUBMED
Trial
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
31 Aug 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
TROP2 NMR Concordance Study
13 Aug 2026· NA · RECRUITING· CTGOV
Publication
Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis.
13 Aug 2026· Current issues in molecular biology· PUBMED
Publication
Adipocyte-derived estrogen signaling influences TROP2 expression in ERα-positive breast cancer.
12 Aug 2026· Frontiers in endocrinology· PUBMED
Trial
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
11 Aug 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
TROP-2 and Nectin-4 Expression in Muscle-Invasive Urothelial and Rare Non-Urothelial Bladder Carcinoma: Association with Tumour Stage and Clinical Outcome.
11 Aug 2026· Cancers· PUBMED
Publication
Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes.
7 Aug 2026· Gynecologic oncology· PUBMED
Publication
TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome.
6 Aug 2026· Frontiers in oncology· PUBMED
Publication
Prognostic and therapeutic importance of TROP-2 and MUC-1 in non-small cell lung cancer: A systematic review and meta-analysis.
5 Aug 2026· Biomedical reports· PUBMED
Trial
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
1 Aug 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV